Deardorf Caren sold (to issuer) $1.9M of CRNX
Deardorf Caren sold (to issuer) 22,225 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($1.89M total) across 2 trades on 2026-09-01.
How this was made
The 30-second read
Why it matters
Director's complete exit may be interpreted as a bearish sign, but size is modest relative to market cap.
Market read
Primary disclosure of insider sell; limited trading relevance but worth noting for short-term sentiment.
What to watch
Sale could be part of a pre-arranged liquidity plan unrelated to company outlook.
Background
SEC Form 4 filing discloses insider transactions for public companies.
Ticker impact
Director Caren Deardorf sold 22,225 shares for $1.889M, reducing holdings to zero.
Potential short-term downside as market digests insider exit.
Sale size is modest but director fully exited; market may view as negative.
Market effects
Minimal impact on biotech sector; isolated insider transaction.
None
None
Counterpoint
Insider may be reallocating capital, not necessarily a negative signal.
Key entities
- CompanyCrinetics Pharmaceuticals, Inc.
Biotech firm listed on NASDAQ.
- InsiderCaren Deardorf
Director of Crinetics who sold shares.
